5 results
Primary ObjectiveTo evaluate the efficacy and safety/tolerability of UK-432,097 DPI in adults with moderate to severe COPD (GOLD stage II/III).
The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in subjects >= 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
The primary objective is to compare antibody responses against the pneumococcal vaccine strains and Influenza virus vaccine types in blood and saliva of older individuals with respect to frailty, taking sex differences into account. The overall aim…
The primary objective is to assess the long-term safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152)in subjects with PN
The primary objective is to assess quantitative antibody responses and functional T-cell and memory B-cell responses to SARS-CoV-2 vaccines in blood of older individuals 64-90 years of age at 28 days after the second vaccination. These response will…